Rapid drug development. Marrying diagnostics with therapeutics is good. Taking the power-couple offshore for fast and low-cost manufacturing is great. A chemical engineer educated at UC Berkeley, Went founded Adamas in 2002 to leverage off-patent drug formulations. His firm optimizes these into new treatments for neurological and infectious diseases, including influenza A, the cause of the current flu pandemic. These are then quickly and cheaply produced at facilities in India. Went is a colleague of, Mickey Urdea. By launching their companies in tandem, the pair hopes to leverage the combination of biomarkers and therapeutics to produce highly targeted products with maximum efficacy. Urdea and Went serve on each other's boards, and also run a consulting firm called Halteres Associates.